Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis

• Published in: Frontiers in oncology Vol. 10; p. 588314
• Main Authors: Wu, Hongyu, Wang, Jianwei, Zhang, Xuanye, Yang, Hang, Wang, Yu, Sun, Peng, Cai, Qingqing, Xia, Yi, Liu, Panpan
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 20.10.2020
• Subjects: immunotherapy; mantle cell lymphoma; non-Hodgkin lymphoma; Oncology; SEER program; survival
• DOI: 10.3389/fonc.2020.588314
• ISSN: 2234-943X

Purpose: The treatment paradigm for mantle cell lymphoma (MCL), a B-cell malignancy, has shifted considerably during the past decades. This study aimed to evaluate time trends in overall survival (OS) and disease-specific mortality (DSM) of younger (age ≤ 65 years) patients with MCL from 1995 to 2016. Methods: We used the Surveillance, Epidemiology, and End Results database. Year of diagnosis was divided into three eras: the chemotherapy-alone era (1995–2000), intensified-immunochemotherapy era (2001–2012), and targeted-therapy era (2013–2016). We used the Kaplan–Meier method, log-rank test, and subdistribution proportional hazard regression in the analysis. Results: A total 4,892 patients were identified. Median OS increased from 67 months in the chemotherapy-alone era to 107 months in the intensified-immunochemotherapy era ( P < 0.001). The DSM rate decreased significantly from 1995 to 2016 ( P < 0.001); the adjusted hazard ratios of MCL-specific death were 0.589 ( P < 0.001) for the intensified-immunochemotherapy era and 0.459 ( P < 0.001) for targeted-therapy era, as compared with the chemotherapy-alone era. Patients with advanced-stage MCL exhibited lowering risk of death across the three eras ( P < 0.001). Conclusions: During 1995–2016, survival in younger patients with MCL increased significantly, especially those with advanced-stage disease, potentially reflecting the impact of advancement in treatment modalities on MCL outcome.